Agios Pharmaceuticals (AGIO) Current Deferred Revenue (2012 - 2022)

Agios Pharmaceuticals (AGIO) has 10 years of Current Deferred Revenue data on file, last reported at $2.5 million in Q1 2022.

• Quarterly Current Deferred Revenue changed N/A year-over-year to $2.5 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $2.5 million (changed N/A YoY) and the FY2019 annual result came in at $61.5 million, down 33.51% from the prior year.
• Current Deferred Revenue eased to $2.5 million in Q1 2022, from $4.7 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $92.5 million in Q4 2018 to a low of $2.5 million in Q1 2022.
• A 4-year average of $34.1 million and a median of $30.7 million in 2018 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2018 — Current Deferred Revenue increased 17.49% — and 2020, when it slumped 78.58%.
• Tracing AGIO's Current Deferred Revenue over 4 years: stood at $92.5 million in 2018, then slumped by 33.51% to $61.5 million in 2019, then tumbled by 92.28% to $4.7 million in 2020, then sank by 47.35% to $2.5 million in 2022.
• The last three Current Deferred Revenue figures came in at $2.5 million (Q1 2022), $4.7 million (Q1 2020), and $61.5 million (Q4 2019), per Business Quant data.